Salarius jumps after completing merger with Decoy Therapeutics
Shares of drug developer Salarius Pharmaceuticals SLRX.O rise 17.3% to $1.22 in early trading
Co and Decoy Therapeutics complete their merger, combining resources to accelerate development of peptide-based drugs for serious diseases - SLRX
The merged co is renamed Decoy Therapeutics and focuses on advancing Decoy's pipeline, which includes treatments for respiratory infections and gastrointestinal cancers, co says
SLRX says Frederick "Rick" Pierce, Decoy's co-founder, serves as chief executive officer
Decoy's technology uses artificial intelligence and rapid manufacturing techniques to design and produce drug candidates quickly - SLRX
Decoy secures funding from institutional investors and programs run by Massachusetts Life Sciences, Google, NVIDIA, and Johnson & Johnson
Including session's move, stock down ~94% YTD
Related Articles
Netflix Stock Analysis: Why Netflix Stock Keeps Falling, and When Should Investors Buy Netflix Stock?
While the final terms for Netflix's acquisition of WBD remain uncertain in the short term, we view the recent decline, driven by market sentiment, as a significant long-term undervalued opportunity. The return to more realistic valuations enhances the investment appeal of Netflix stock.
Musk Confirms SpaceX 2026 IPO: The Dual ‘Trillion-Dollar’ Bet with Hidden Risks
TradingKey - Elon Musk has confirmed speculation that his space exploration company, SpaceX, is preparing for an IPO as early as 2026. The potential listing, which could value SpaceX at over $1 trillion, might catapult it into the ranks of the world's top ten most valuable companies. This raises a
Judgment on the Fed's December Rate Cut and 2026 Monetary Policy Trend: Identifying Opportunities in the U.S. Stock Market
TradingKey - The Federal Reserve is likely to halt its rate-cutting cycle before the end of Q2 2026...The magnitude of rate cuts in Q3 and Q4 2026 is expected to far exceed current market expectations...U.S. equities are highly likely to follow a "bearish-then-bullish" trajectory throughout 2026.
Why Is the "Altcoin Season" Delayed? Will Altcoins Perish?
The anticipated "altcoin season" has yet to materialize, constrained by a lack of fresh market capital and Bitcoin's continued dominance in absorbing available funds. This does not mean all altcoins will perish; however, a segment of these tokens will gradually exit the market. Therefore, caution is
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?
